NO993600L - Treatment of autoimmune disease Õ use "tolerization" in combination with methotrexate - Google Patents

Treatment of autoimmune disease Õ use "tolerization" in combination with methotrexate

Info

Publication number
NO993600L
NO993600L NO993600A NO993600A NO993600L NO 993600 L NO993600 L NO 993600L NO 993600 A NO993600 A NO 993600A NO 993600 A NO993600 A NO 993600A NO 993600 L NO993600 L NO 993600L
Authority
NO
Norway
Prior art keywords
methotrexate
combination
autoimmune disease
tolerization
treatment
Prior art date
Application number
NO993600A
Other languages
Norwegian (no)
Other versions
NO993600D0 (en
Inventor
Howard L Weiner
Ahmad Al-Sabbagh
Patricia A Nelson
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of NO993600D0 publication Critical patent/NO993600D0/en
Publication of NO993600L publication Critical patent/NO993600L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En kombinasjon en mukøs administrering eller bystander antigen og en oral, enteral eller parenteral administrerbar metotreksat er anvendt for å fremstille en farmasøytisk formulering og for å behandle eller forhindre autoimmun sykdom. Mengdene av bystander antigen og metotreksat er effektiv i kombinasjon for å undetrykke autoimmun respons assosiert med den autoimmune sykdommen.A combination of a mucous administration or bystander antigen and an oral, enteral or parenterally administrable methotrexate is used to prepare a pharmaceutical formulation and to treat or prevent autoimmune disease. The amounts of bystander antigen and methotrexate are effective in combination to suppress the autoimmune response associated with the autoimmune disease.

NO993600A 1997-01-24 1999-07-23 Treatment of autoimmune disease Õ use "tolerization" in combination with methotrexate NO993600L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (2)

Publication Number Publication Date
NO993600D0 NO993600D0 (en) 1999-07-23
NO993600L true NO993600L (en) 1999-09-23

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993600A NO993600L (en) 1997-01-24 1999-07-23 Treatment of autoimmune disease Õ use "tolerization" in combination with methotrexate

Country Status (10)

Country Link
EP (1) EP0994717A4 (en)
JP (1) JP2001511134A (en)
KR (1) KR20000070460A (en)
AU (1) AU6648898A (en)
BR (1) BR9807112A (en)
CA (1) CA2278152A1 (en)
HU (1) HUP0001960A2 (en)
IL (1) IL131025A0 (en)
NO (1) NO993600L (en)
WO (1) WO1998032451A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60323729D1 (en) 2002-02-11 2008-11-06 Antares Pharma Inc INTRADERMAL INJECTION DEVICE
BRPI0614025A2 (en) 2005-01-24 2012-12-25 Antares Pharma Inc jet injectors
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
WO2009114542A1 (en) 2008-03-10 2009-09-17 Antares Pharma, Inc. Injector safety device
US8376993B2 (en) 2008-08-05 2013-02-19 Antares Pharma, Inc. Multiple dosage injector
CA2755779C (en) 2009-03-20 2015-11-10 Antares Pharma, Inc. Hazardous agent injection system
US9044479B2 (en) 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
WO2013134244A2 (en) 2012-03-06 2013-09-12 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
EP4186545A1 (en) 2012-04-06 2023-05-31 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
WO2013169804A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
EP4349383A3 (en) 2013-02-11 2024-06-19 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
EP3572108A1 (en) 2013-03-11 2019-11-27 Antares Pharma, Inc. Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
AU2014249456B2 (en) 2013-03-13 2018-08-09 IRR, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EP3308835B1 (en) 2013-03-13 2020-01-01 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN105263579B (en) 2013-03-13 2020-01-10 炎症反应研究公司 Use of levocetirizine and montelukast in the treatment of vasculitis
JP2017526728A (en) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Levocetirizine and montelukast in the treatment of inflammation-mediated conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
JP2512796B2 (en) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド Treatment of autoimmune disease by oral administration of self-antigen
JPH05507501A (en) * 1990-09-06 1993-10-28 リックスウーニーベルシテイト・テ・ウットレヒト Inhibitors of lymphocyte responses and immune-related diseases
KR950700082A (en) * 1992-02-28 1995-01-16 로버트 씨. 비숍 How to Treat Autoimmune Diseases by Bystander
AU5960096A (en) * 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t ce lls
EP0834321B1 (en) * 1995-06-13 2003-05-02 Nippon Meat Packers, Inc. Oral remedy for rheumatoid arthritis and functional food

Also Published As

Publication number Publication date
WO1998032451A1 (en) 1998-07-30
BR9807112A (en) 2001-09-18
KR20000070460A (en) 2000-11-25
EP0994717A4 (en) 2000-07-26
NO993600D0 (en) 1999-07-23
HUP0001960A2 (en) 2000-10-28
IL131025A0 (en) 2001-01-28
CA2278152A1 (en) 1998-07-30
JP2001511134A (en) 2001-08-07
EP0994717A1 (en) 2000-04-26
AU6648898A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
NO993600L (en) Treatment of autoimmune disease Õ use "tolerization" in combination with methotrexate
AU2634592A (en) Improved interferon therapy
NZ293542A (en) Treatment of bowel microflora to relive neurological disorders
HUT74832A (en) Method and compositions for treatment of autoimmune diseases by use of bystander antigen
DE69731610D1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
EP0957925A4 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
AU2795395A (en) Novel therapeutic and dietetic uses of a brain phospholipid-based complex
王庆其 Advances in treatment of epilepsy with traditional Chinese medicine
孙丽琴 TREATMENT OF RHEU MATOID ARTHRITIS BY WARMING NEEDLE
Maher et al. Commentary: making tuberculosis treatment available for all.
胡军 et al. COMPARISON ON THE CLINICAL EFFECT IN THE TREATMENT OF HYPERTHYROIDISM WITH DIFFERENT ACUPUNCTURE INTERVAL
WO1999038524A3 (en) Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation
Lavaroni et al. Hallopeau's acrodermatitis treated with cyclosporin Aa case report
胡金生 Acupuncture treatment of epigastric pain
王芳妮 Clinical Observation on Treatment of 120 Cases of Periphery Facial Paralysis with Penetration Needling
李征宇 et al. Observations on the effects of massage on experimental gastric ulcer in rats
Bowersox ACTG 152: new insights into pediatric antiretroviral therapy
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
杨露 et al. Chloasma Treated Mainly with Facial Acupuncture
施婷 et al. An analysis of the relative specificity of acupoints in sciatica models
邵永金 et al. A survey on acupuncture treatment of peripheral nerve injury
周立群 How to Promote the Therapeutic Effect of Auriculotherapy in the Treatment of Vascular Hypertension?
王润 Treatment of 40 cases of hydroceles with massage at Qichong (ST 30)
黄巍 et al. CLINICAL OBSERVATION ON THE TREATMENT OF LUMBAR VERTEBRA HYPEROSTEOGENY WITH ELECTRO-AND HYDRO-ACUPUNCTURE
王征美 et al. CLINICAL STUDIES ON THE TREATMENT OF PARAPLEGIC PATIENTS'PAIN WITH ACUPUNCTURE